Calcitonin oral - Biocon/Seachaid Pharmaceuticals

Drug Profile

Calcitonin oral - Biocon/Seachaid Pharmaceuticals

Alternative Names: CT 025; NCT-025; Oratonin

Latest Information Update: 21 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biocon
  • Developer Seachaid Pharmaceuticals
  • Class Antihypercalcaemics; Calcium regulators; Neuropeptides; Osteoporosis therapies; Peptide hormones
  • Mechanism of Action Calcitonin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Postmenopausal osteoporosis

Most Recent Events

  • 02 Apr 2004 The Synerobex joint venture between Nobex Corporation and Elan Corporation has been dissolved; Oratonin™ is now owned solely by Nobex
  • 24 Mar 2004 Oratonin™ is available for licensing worldwide (http://www.nobexcorp.com)
  • 17 Apr 2002 Phase-I clinical trials in Postmenopausal osteoporosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top